NCT02960945

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

An Open-Label Single-Dose Crossover Pharmacokinetic Study to Compare CTP-543 to Jakafi® in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Concert Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study will assess the metabolite and pharmacokinetic (PK) profile of a single dose of CTP-543 compared to a single dose of Jakafi® in healthy volunteers.

Detailed description

The crossover design will assess the safety, tolerability, PK and metabolite profiles of a single dose of CTP-543 compared to a single dose of Jakafi. Approximately 12 healthy volunteers will be enrolled in this open label study.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	CTP-543, 16 mg (2 x 8 mg tablet)
DRUG	Jakafi 15Mg Tablet

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-01-01
• Completion: 2017-03-01
• First posted: 2016-11-10
• Last updated: 2017-03-28

Locations

1 site across 1 country: United States